NCT04541888View on ClinicalTrials.gov

Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

644

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

August 16, 2021

Study Completion Date

October 14, 2021

Conditions
Dry Eye
Interventions
DRUG

CsA Ophthalmic Gel

The CsA eye gel of 0.3 g: 0.15 mg

DRUG

Placebo

Placebo

DRUG

Hypromellose Eye Drop

Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop

Trial Locations (1)

510060

Ophthalmological Center of Zhongshan University, Guangzhou

All Listed Sponsors
lead

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

INDUSTRY

NCT04541888 - Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease | Biotech Hunter | Biotech Hunter